Bladder, Overactive
7
1
1
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
14%
1 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (7)
Low-Energy Shock Wave Therapy for Overactive Bladder in Women With Metabolic Syndrome
Efficacy of Vaginal 17β-Estradiol on the Urinary Storage Symptoms in Postmenopausal Women
Laser Treatment of Genito-urinary Syndrome in Women
Transvaginal Botulinum Toxin A Chemodenervation for Overactive Bladder
Effect of Medical Cannabis for Non-motor Symptoms of Parkinson's Disease
Genital Nerve Stimulation - GNS - for Treatment of Non-neurogenic OAB
Evaluation of Professional Practices in the Treatment of Refractory Idiopathic Overactive Bladder at the Dose of 50 Units (TOX50IUU)